IKT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
今日成交量	98 979.00
平均成交量	103 828
市值	11.08M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0260 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.54
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

音量相关性

長: -0.10 (neutral)

短: -0.36 (neutral)

Signal:(46.053) Neutral

Inhibikase Therapeutics, 相关性

10 最正相关
SVOK	0.82

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Inhibikase Therapeutics, 相关性 - 货币/商品

0.31
( neutral )

0.06
( neutral )

0.00
( neutral )

0.52
( weak )

-0.21
( neutral )

-0.12
( neutral )

Inhibikase Therapeutics, 财务报表

Annual	2023
营收:	$260 500
毛利润:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
营收:	$260 500
毛利润:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
营收:	$123 440
毛利润:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
营收:	$3.10M
毛利润:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.